Convection enhanced delivery of macromolecules for brain tumors
- PMID: 22339074
- PMCID: PMC7521418
- DOI: 10.2174/157016312803305951
Convection enhanced delivery of macromolecules for brain tumors
Abstract
The blood brain barrier (BBB) poses a significant challenge for drug delivery of macromolecules into the brain. Convection-enhanced delivery (CED) circumvents the BBB through direct intracerebral infusion using a hydrostatic pressure gradient to transfer therapeutic compounds. The efficacy of CED is dependent on the distribution of the therapeutic agent to the targeted region. Here we present a review of convection enhanced delivery of macromolecules, emphasizing the role of tracers in enabling effective delivery anddiscuss current challenges in the field.
Conflict of interest statement
CONFLICT OF INTEREST
None declared.
Similar articles
-
Imaging of convection enhanced delivery of toxins in humans.Toxins (Basel). 2011 Mar;3(3):201-6. doi: 10.3390/toxins3030201. Epub 2011 Mar 15. Toxins (Basel). 2011. PMID: 22069706 Free PMC article. Review.
-
Convection-enhanced Delivery of Therapeutics for Malignant Gliomas.Neurol Med Chir (Tokyo). 2017 Jan 15;57(1):8-16. doi: 10.2176/nmc.ra.2016-0071. Epub 2016 Dec 15. Neurol Med Chir (Tokyo). 2017. PMID: 27980285 Free PMC article. Review.
-
Convection and retro-convection enhanced delivery: some theoretical considerations related to drug targeting.Pharm Res. 2011 Mar;28(3):472-9. doi: 10.1007/s11095-010-0296-2. Epub 2010 Oct 21. Pharm Res. 2011. PMID: 20963628 Free PMC article.
-
Convection-enhanced drug delivery for glioblastoma: a review.J Neurooncol. 2021 Feb;151(3):415-427. doi: 10.1007/s11060-020-03408-9. Epub 2021 Feb 21. J Neurooncol. 2021. PMID: 33611708 Free PMC article. Review.
-
Convection enhanced delivery for the treatment of malignant gliomas: symposium review.J Neurooncol. 2005 May;73(1):57-69. doi: 10.1007/s11060-004-2243-8. J Neurooncol. 2005. PMID: 15933820
Cited by
-
Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme.CNS Oncol. 2015;4(2):63-9. doi: 10.2217/cns.14.54. CNS Oncol. 2015. PMID: 25768330 Free PMC article. Review.
-
Comprehensive insights into glioblastoma multiforme: drug delivery challenges and multimodal treatment strategies.Ther Deliv. 2025 Jan;16(1):87-115. doi: 10.1080/20415990.2024.2415281. Epub 2024 Oct 24. Ther Deliv. 2025. PMID: 39445563 Review.
-
Radiation therapy combined with intracerebral administration of carboplatin for the treatment of brain tumors.Radiat Oncol. 2014 Jan 14;9:25. doi: 10.1186/1748-717X-9-25. Radiat Oncol. 2014. PMID: 24422671 Free PMC article.
-
Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies.J Hematol Oncol. 2022 Nov 12;15(1):165. doi: 10.1186/s13045-022-01383-4. J Hematol Oncol. 2022. PMID: 36371226 Free PMC article. Clinical Trial.
-
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.J Clin Oncol. 2018 May 10;36(14):1419-1427. doi: 10.1200/JCO.2017.75.8219. Epub 2018 Feb 12. J Clin Oncol. 2018. PMID: 29432077 Free PMC article. Clinical Trial.
References
-
- Kanu OO, Mehta A, Di C, et al. Glioblastoma multiforme: a review of therapeutic targets. Expert Opin Ther Targets 2009; 13(6): 701–18. - PubMed
-
- Reardon DA, Rich JN, Friedman HS, et al. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 2006; 24(8): 1253–65. - PubMed
-
- Muldoon LL, Soussain C, Jahnke K, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007; 25(16): 2295–305. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical